Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics (NASDAQ:IMMU)

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology & Medical Research - NEC
Sub-Industry: Biotechnology
Symbol: NASDAQ:IMMU
CUSIP: 45290710
Web: www.immunomedics.com

Capitalization:

Market Cap: $870.25 million
Outstanding Shares: 110,298,000

Average Prices:

50 Day Moving Avg: $8.55
200 Day Moving Avg: $6.87
52 Week Range: $2.02 - $9.51

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -16.41
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $3.38 million
Price / Sales: 262.37
Book Value: ($1.20) per share
Price / Book: -6.70

Profitability:

EBIDTA: ($63,800,000.00)
Net Margins: -3,426.56%
Return on Assets: -142.88%

Debt:

Debt-to-Equity Ratio: -0.74%
Current Ratio: 0.57%
Quick Ratio: 0.56%

Misc:

Average Volume: 2.10 million shs.
Beta: 1.71
Short Ratio: 13.63

Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its earnings results on Thursday, February, 9th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.03. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.70 million. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

3 brokers have issued 1 year price targets for Immunomedics' shares. Their forecasts range from $11.00 to $15.00. On average, they anticipate Immunomedics' stock price to reach $13.00 in the next year. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 34,023,565 shares, an increase of 1.9% from the July 14th total of 34,673,820 shares. Based on an average daily volume of 1,532,131 shares, the short-interest ratio is currently 22.2 days. Currently, 33.9% of the shares of the stock are sold short.

Who are some of Immunomedics' key competitors?

Some companies that are related to Immunomedics include Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Esperion Therapeutics (ESPR), Medpace Holdings (MEDP), Momenta Pharmaceuticals (MNTA), Genus plc (GNS), Genomic Health (GHDX), Editas Medicine (EDIT), Albany Molecular Research (AMRI), BeyondSpring (BYSI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Spectrum Pharmaceuticals (SPPI), CRISPR THERAPTC (CRSP), TG Therapeutics (TGTX), Cellectis S.A. (CLLS) and Enanta Pharmaceuticals (ENTA).

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

Jason M. Aryeh, Chairman of the Board
Cynthia L. Sullivan, President, Chief Executive Officer, Director
Michael R. Garone, Chief Financial Officer, Vice President - Finance
David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director
Geoffrey F. Cox Ph.D., Independent Director
Robert Forrester, Independent Director
Brian A. Markison, Lead Independent Director
Bob Oliver, Independent Director

Who owns Immunomedics stock?

Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (5.02%), State Street Corp (4.37%), Vanguard Group Inc. (4.13%), Farallon Capital Management LLC (3.83%), Palo Alto Investors LLC (2.73%) and First Light Asset Management LLC (1.86%). Company insiders that own Immunomedics stock include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Chicago Equity Partners LLC, Virtu KCG Holdings LLC, First Light Asset Management LLC, Atlantic Trust Group LLC, UBS Asset Management Americas Inc., IFP Advisors Inc and Swiss National Bank. Company insiders that have sold Immunomedics stock in the last year include Don C Stark and Mary E Paetzold. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Palo Alto Investors LLC, State Street Corp, Jennison Associates LLC, Goldman Sachs Group Inc., DAFNA Capital Management LLC, EAM Investors LLC and Gotham Asset Management LLC. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $8.04.

MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		123 (Vote Outperform)
Underperform Votes:		101 (Vote Underperform)
Total Votes:		224

MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	3 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$13.00 (61.69% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
7/24/2017	Cowen and Company	Reiterated Rating	Outperform	$15.00	Low
7/14/2017	Jefferies Group LLC	Reiterated Rating	Buy	$11.00	Low
5/5/2017	Wells Fargo & Company	Upgrade	Market Perform -> Outperform		High

(Data available from 8/16/2015 forward)

Earnings History for Immunomedics (NASDAQ:IMMU)

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Earnings History by Quarter for Immunomedics (NASDAQ IMMU)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/9/2017	Q2 2017	($0.13)	($0.16)	$0.70 million	$0.38 million	View	Listen
11/2/2016	Q117	($0.14)	($0.17)	$0.70 million	$0.74 million	View	N/A
8/17/2016	Q416	($0.11)	($0.17)	$0.90 million	$0.93 million	View	Listen
5/4/2016	Q3	($0.13)	($0.15)	$0.70 million	$0.90 million	View	N/A
2/3/2016	Q216	($0.14)	($0.15)	$1.40 million	$0.67 million	View	N/A
11/4/2015	Q116	($0.14)	($0.16)	$1.23 million	$0.73 million	View	N/A
8/19/2015	Q415	($0.13)	($0.13)	$1.13 million	$2.40 million	View	Listen
5/6/2015	Q3 2015	($0.13)	($0.13)	$1.07 million	$1.18 million	View	N/A
2/4/2015	Q215	($0.13)	($0.12)	$1.73 million	$1.00 million	View	N/A
11/5/2014	Q1 2015	($0.12)	($0.13)	$1.18 million	$1.07 million	View	N/A
8/25/2014	Q414	($0.13)	($0.13)	$1.20 million	$1.20 million	View	N/A
5/7/2014	Q3 2014	($0.12)	$0.02	$1.13 million	$1.15 million	View	N/A
2/10/2014	Q214	($0.10)	($0.10)	$1.20 million	$1.20 million	View	N/A
8/22/2013	Q4 2013	($0.12)	($0.09)	$0.81 million	$1.40 million	View	N/A
5/8/2013	Q3 2013	($0.10)	$0.11	$0.97 million	$1.70 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Immunomedics (NASDAQ:IMMU)

2017 EPS Consensus Estimate: ($0.53)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.12)	($0.12)	($0.12)
Q2 2017	1	($0.15)	($0.15)	($0.15)
Q3 2017	1	($0.15)	($0.15)	($0.15)
Q4 2017	1	($0.11)	($0.11)	($0.11)

(Data provided by Zacks Investment Research)

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)

Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 63.39%

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/24/2016	Don C Stark	Director	Sell	9,900	$2.97	$29,403.00
8/23/2016	Mary E Paetzold	Director	Sell	15,000	$2.98	$44,700.00
6/13/2016	Cynthia L Goldenberg	CEO	Sell	371,990	$3.03	$1,127,129.70
6/8/2016	Cynthia L Goldenberg	CEO	Sell	41,441	$3.62	$150,016.42
6/8/2016	David M Goldenberg	Chairman	Sell	353,010	$3.88	$1,369,678.80
6/7/2016	Cynthia L Goldenberg	CEO	Sell	4,600	$4.01	$18,446.00
6/7/2016	David M Goldenberg	Chairman	Sell	12,300	$3.98	$48,954.00
6/6/2016	Cynthia L Goldenberg	CEO	Sell	63,959	$4.09	$261,592.31
6/6/2016	David M Goldenberg	Chairman	Sell	110,322	$4.09	$451,216.98
6/15/2015	David M Goldenberg	Chairman	Sell	210,991	$4.08	$860,843.28
6/12/2015	Brian A Markison	Director	Sell	5,564	$4.22	$23,480.08
6/12/2015	David M Goldenberg	Chairman	Sell	359,653	$4.32	$1,553,700.96
6/9/2015	Mary E Paetzold	Director	Sell	4,677	$4.60	$21,514.20
6/5/2015	Don C Stark	Director	Sell	5,732	$4.14	$23,730.48
12/11/2014	Mary E Paetzold	Director	Sell	10,000	$4.71	$47,100.00
12/9/2014	Don C Stark	Director	Sell	5,500	$4.51	$24,805.00
9/13/2013	Don Stark	Director	Sell	10,000	$6.08	$60,800.00

(Data available from 1/1/2013 forward)

Headline Trends for Immunomedics (NASDAQ:IMMU) Latest Headlines for Immunomedics (NASDAQ:IMMU)

Source:

Date	Headline
	Zacks Investment Research Lowers Immunomedics, Inc. (IMMU) to Hold www.americanbankingnews.com - August 11 at 12:28 AM
	Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results finance.yahoo.com - August 7 at 7:15 PM
	Immunomedics, Inc. (IMMU) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - August 4 at 11:52 PM
	BRIEF-Immunomedics, Covance enter into master services agreement www.reuters.com - August 4 at 8:07 PM
	Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017 finance.yahoo.com - August 3 at 7:57 PM
	Immunomedics, Inc. (IMMU) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - July 25 at 3:07 PM
	Cowen and Company Reaffirms Outperform Rating for Immunomedics, Inc. (NASDAQ:IMMU) www.americanbankingnews.com - July 24 at 4:10 PM
	Immunomedics, Inc. (IMMU) Raised to "Buy" at Zacks Investment Research www.americanbankingnews.com - July 18 at 12:56 AM
	FY2019 Earnings Forecast for Immunomedics, Inc. (NASDAQ:IMMU) Issued By Jefferies Group www.americanbankingnews.com - July 17 at 11:11 AM
	Jefferies Group LLC Reaffirms "Buy" Rating for Immunomedics, Inc. (IMMU) www.americanbankingnews.com - July 15 at 4:12 PM
	Jefferies Group Comments on Immunomedics, Inc.'s FY2022 Earnings (IMMU) www.americanbankingnews.com - July 14 at 3:56 PM
	Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics’ Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers finance.yahoo.com - July 10 at 7:51 PM
	ETFs with exposure to Immunomedics, Inc. : July 10, 2017 finance.yahoo.com - July 10 at 7:51 PM
	Pre-Market Most Active for Jul 3, 2017 : SIRI, MU, PBR, IMMU, VIPS, BAC, USLV, TSLA, SPIL, RAD, NRG, CHK - Nasdaq www.nasdaq.com - July 3 at 7:20 PM
	Form 8-K IMMUNOMEDICS INC For: Jun 29 - StreetInsider.com www.streetinsider.com - July 1 at 1:00 AM
	Immunomedics Announces Results of Special Stockholder Meeting - Nasdaq www.nasdaq.com - June 30 at 5:14 AM
	Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock finance.yahoo.com - June 30 at 12:10 AM
	Immunomedics Announces Results of Special Stockholder Meeting finance.yahoo.com - June 30 at 12:10 AM
	Immunomedics, Inc. (IMMU) Short Interest Update www.americanbankingnews.com - June 28 at 7:14 AM
	ETFs with exposure to Immunomedics, Inc. : June 27, 2017 finance.yahoo.com - June 27 at 6:06 PM
	ETFs with exposure to Immunomedics, Inc. : June 16, 2017 finance.yahoo.com - June 16 at 6:44 PM
	Immunomedics, Inc. (IMMU) Given a $9.00 Price Target by Jefferies Group LLC Analysts www.americanbankingnews.com - June 11 at 10:52 PM
	Three Junior Biotechs Ready to Run (IMMU, STDY) www.investopedia.com - June 7 at 5:28 PM
	ETFs with exposure to Immunomedics, Inc. : June 5, 2017 finance.yahoo.com - June 5 at 5:56 PM
	Immunomedics, Inc. (IMMU) Raised to "Hold" at ValuEngine www.americanbankingnews.com - June 4 at 11:14 AM
	Immunomedics to Present at Jefferies 2017 Global Healthcare Conference finance.yahoo.com - June 1 at 6:44 PM
	Immunomedics, Inc. (IMMU) Coverage Initiated at Cowen and Company www.americanbankingnews.com - May 26 at 2:52 PM
	ETFs with exposure to Immunomedics, Inc. : May 25, 2017 finance.yahoo.com - May 26 at 2:17 AM
	Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017 finance.yahoo.com - May 24 at 11:33 AM
	Company Spotlight: Immunomedics www.rttnews.com - May 12 at 6:36 PM
	Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT finance.yahoo.com - May 12 at 2:04 AM
	Immunomedics, Inc. (IMMU) Short Interest Up 12.4% in April www.americanbankingnews.com - May 11 at 7:34 AM
	BRIEF-Immunomedics Q3 loss per share $0.55 www.reuters.com - May 10 at 6:22 PM
	Immunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments finance.yahoo.com - May 10 at 6:22 PM
	Immunomedics reports 3Q loss finance.yahoo.com - May 10 at 6:22 PM
	Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results finance.yahoo.com - May 10 at 1:20 PM
	Equities Analysts Issue Forecasts for Immunomedics, Inc.'s FY2017 Earnings (IMMU) www.americanbankingnews.com - May 10 at 9:58 AM
	Immunomedics (IMMU) Earns Daily Coverage Optimism Score of 0.19 www.americanbankingnews.com - May 9 at 12:50 AM
	Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017 finance.yahoo.com - May 8 at 5:33 PM
	Biotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics www.bizjournals.com - May 8 at 7:18 AM
	Immunomedics Breaks Out, But Will It Last? finance.yahoo.com - May 8 at 7:18 AM
	Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated? finance.yahoo.com - May 6 at 9:50 AM
	Immunomedics (IMMU) Receives Daily Media Sentiment Score of 0.22 www.americanbankingnews.com - May 5 at 11:22 PM
	BRIEF-Immunomedics announces private placement offering www.reuters.com - May 5 at 10:54 PM
	Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value finance.yahoo.com - May 5 at 10:54 PM
	BRIEF-Immunomedics announces private placement offering - Reuters www.reuters.com - May 5 at 5:52 PM
	Why Immunomedics, Inc. Rocketed Today - Motley Fool www.fool.com - May 5 at 5:52 PM
	Why Immunomedics, MercadoLibre, and Pearson Jumped Today finance.yahoo.com - May 5 at 5:52 PM
	Immunomedics, Seattle Genetics Scrap License Deal finance.yahoo.com - May 5 at 5:52 PM
	Why Immunomedics, Inc. Rocketed Today www.fool.com - May 5 at 2:53 PM